NCT03311581View on ClinicalTrials.gov

The Feasibility of Propofol TCI in Hemodialysis Patients Undergoing Arteriovenous Shunt Surgery

PHASE1CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

September 11, 2017

Primary Completion Date

June 4, 2021

Study Completion Date

June 4, 2021

Conditions
End Stage Renal DiseaseHemodialysis Complication
Interventions
DRUG

Propofol

Propofol works by increasing GABA-mediated inhibitory tone in the CNS. Propofol decreases the rate of dissociation of the GABA from the receptor, thereby increasing the duration of the GABA-activated opening of the chloride channel with resulting hyperpolarization of cell membranes.

DEVICE

Sevoflurane

sevoflurane inhalation 2\~4%

Trial Locations (1)

807

Kaohsiung Medical University Hospital, Kaohsiung City

All Listed Sponsors
lead

Kaohsiung Medical University Chung-Ho Memorial Hospital

OTHER

NCT03311581 - The Feasibility of Propofol TCI in Hemodialysis Patients Undergoing Arteriovenous Shunt Surgery | Biotech Hunter | Biotech Hunter